Zydus Cadila has received the tentative approval from the USFDA to market Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg. It is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 5.45, or 1.36%, to trade at Rs 406.00. The total volume of shares traded was 74,913 at the BSE (12.10 p.m., Tuesday).